MarketMoversReport

Axsome Therapeutics Announces FDA Approval of AUVELITY™

Long
NASDAQ:AXSM   Axsome Therapeutics, Inc
AXSM: Axsome Therapeutics , Inc.
2022-08-19 Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.